Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - Haematological malignancies

826O - Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the phase III CHRONOS-3 trial

Date

20 Sep 2021

Session

Proffered Paper session - Haematological malignancies

Topics

Cytotoxic Therapy

Tumour Site

Lymphomas

Presenters

Muhit Özcan

Citation

Annals of Oncology (2021) 32 (suppl_5): S773-S785. 10.1016/annonc/annonc676

Authors

M. Özcan1, J. Jin2, Á. Szomor3, P. Panayiotidis4, D.H. Yoon5, A.M. Tyczynska6, L. Mongay Soler7, A. Cao8, F. Hiemeyer9, B.H. Childs7, M.J. Matasar10, P.L. Zinzani11

Author affiliations

  • 1 Department Of Hematology, Ankara University School of Medicine, 06590 - Ankara/TR
  • 2 Department Of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou/CN
  • 3 Department Of Hematology, Pécsi Tudományegyetem Klinikai Központ, 7623 - Pécs/HU
  • 4 First Department Of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, 11527 - Athens/GR
  • 5 Department Of Oncology, Asan Medical Center, 138-736 - Seoul/KR
  • 6 Department Of Oncology, University Clinical Centre, Medical University of Gdańsk, 80-210 - Gdańsk/PL
  • 7 Department Of Clinical Development, Bayer HealthCare Pharmaceuticals, Inc., 07981 - Whippany/US
  • 8 Department Of Clinical Statistics, Bayer HealthCare Pharmaceuticals, Inc., 07981 - Whippany/US
  • 9 Department Of Clinical Statistics, Bayer Pharma AG, 13353 - Berlin/DE
  • 10 Department Of Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 11 Irccs Azienda Ospedaliero-universitaria Di Bologna, Istituto Di Ematologia “seràgnoli”; Dipartimento Di Medicina Specialistica, Diagnostica E Sperimentale, Università di Bologna, 40138 - Bologna/IT
More

Resources

Login to access the resources on OncologyPRO.

Abstract 826O

Background

The randomized, double-blind, placebo-controlled phase III CHRONOS-3 study (NCT02367040) showed a 48% risk reduction in disease progression/death with the PI3K inhibitor copanlisib + rituximab (C+R) vs placebo (P)+R in pts with relapsed indolent non-Hodgkin lymphoma (iNHL). We report a subset analysis in pts with MZL.

Methods

Pts with relapsed iNHL progression- and treatment-free for ≥12 months (mo) after R-based therapy or ≥6 mo if unwilling/unfit to receive chemotherapy were randomized 2:1 to C+R or P+R. C 60 mg/P was given i.v. on days (d) 1, 8, and 15 (28-d cycle); R 375 mg/m2 was given i.v. on d 1, 8, 15, and 22 of cycle 1 and d 1 of cycles 3, 5, 7, and 9. Primary endpoint was centrally assessed progression-free survival (PFS).

Results

Of 458 pts in CHRONOS-3, 66 with MZL were randomized to C+R and 29 to P+R. MZL subtypes included nodal (39%), extranodal (37%), and splenic (24%). With a median follow-up of 18.0 mo, C+R significantly reduced the risk of disease progression/death vs P+R; objective response rate (ORR) improved with C+R (Table). Median duration of response was 25.4 mo for C+R vs 9.3 mo for P+R; median time to progression was 33.2 mo vs 11.5 mo. Median overall survival was not evaluable (NE). Most common treatment-emergent adverse events (TEAEs; all grade/grade 3+) with C+R were hyperglycemia (65%/54%) and hypertension (54%/45%). Most common TEAEs with P+R were hyperglycemia (24%/10%), cough (24%/0%) and upper respiratory tract infection (24%/0%). Serious TEAEs were higher with C+R (57%) vs P+R (28%). TEAEs deemed related to C/P included hyperglycemia (63%/24%) and hypertension (54%/17%). Table: 826O

Treatment Overall MZL Nodal MZL Extranodal MZL Splenic MZL
C+R P+R C+R P+R C+R P+R C+R P+R
N 66 29 25 12 24 11 17 6
Median PFS, months (95% CI) 22.1 (13.8, NE) 11.5 (5.6, 16.3) 21.5 (13.1, NE) 11.5 (2.5, NE) NE (9.0, NE) 10.8 (1.6, 35.6) Not reliably estimable
HR (95% CI) C+R vs P+R 0.475 (0.245, 0.923) 0.483 (0.183, 1.276) 0.334 (0.111, 1.010)
1-sided p value 0.012 0.067 0.021
ORR, % ( n ) 75.8 (50) 41.4 (12) 88.0 (22) 33.3 (4) 75.0 (18) 45.5 (5) 58.8 (10) 50.0 (3)
Complete response rate, % ( n ) 39.4 (26) 10.3 (3) 32.0 (8) 8.3 (1) 58.3 (14) 9.1 (1) 23.5 (4) 16.7 (1)

Primary efficacy evaluation for PFS based on unstratified log-rank test and unstratified Cox proportional hazard model

Conclusions

C+R showed superior efficacy vs P+R in pts with relapsed MZL, including nodal MZL. The safety profile of C+R was consistent with C and R as monotherapy. Copanlisib is the first PI3K inhibitor to be safely combined with R in a phase III setting in pts with relapsed MZL and represents a new therapeutic strategy.

Clinical trial identification

NCT02367040.

Editorial acknowledgement

Writing support by Ryan Staudt, PhD, Complete HealthVizion.

Legal entity responsible for the study

Bayer AG.

Funding

Bayer AG.

Disclosure

M. Özcan: Financial Interests, Personal, Other, Honoraria: Amgen; Non-Financial Interests, Personal, Other, Travel support: Amgen; Non-Financial Interests, Personal, Other, Travel support: Bristol Myers Squibb; Financial Interests, Personal, Other, Financial relationships: Abdi İbrahim; Financial Interests, Personal, Other, Financial relationships: Jazz Pharmaceuticals; Financial Interests, Personal, Other, Financial relationships: Sanofi; Financial Interests, Personal, Research Grant: AbbVie; Non-Financial Interests, Personal, Other, Travel support: AbbVie; Financial Interests, Personal, Research Grant: Archigen Biotech; Financial Interests, Personal, Research Grant: Bayer; Financial Interests, Personal, Research Grant: Celgene; Financial Interests, Personal, Research Grant: F. Hoffmann-La Roche Ltd.; Non-Financial Interests, Personal, Other, Travel support: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Research Grant: Janssen; Financial Interests, Personal, Other, Travel support: Janssen; Financial Interests, Personal, Research Grant: MSD; Financial Interests, Personal, Research Grant: Takeda. P. Panayiotidis: Financial Interests, Personal, Other, Honoraria: Genesis; Financial Interests, Personal, Other, Honoraria: Gilead; Financial Interests, Personal, Other, Honoraria: Roche; Financial Interests, Personal, Other, Honoraria: Takeda; Financial Interests, Personal, Research Grant: Genesis; Financial Interests, Personal, Research Grant: Roche; Financial Interests, Personal, Research Grant: Takeda. L. Mongay Soler: Financial Interests, Personal, Full or part-time Employment: Bayer HealthCare Pharmaceuticals, Inc. A. Cao: Financial Interests, Personal, Full or part-time Employment: Bayer HealthCare Pharmaceuticals, Inc. F. Hiemeyer: Financial Interests, Personal, Full or part-time Employment: Bayer AG. B.H. Childs: Financial Interests, Personal, Full or part-time Employment: Bayer HealthCare Pharmaceuticals, Inc. M.J. Matasar: Financial Interests, Personal, Research Grant: Bayer; Financial Interests, Personal, Other, Consultancy, honoraria: Bayer; Financial Interests, Personal, Other, Consultancy: Daiichi Sankyo; Financial Interests, Personal, Research Grant: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Other, Consultancy, honoraria: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Other, Consultancy: Juno Therapeutics; Financial Interests, Personal, Other, Consultancy: Merck; Financial Interests, Personal, Research Grant: Rocket Medical; Financial Interests, Personal, Other, Consultancy: Rocket Medical; Financial Interests, Personal, Research Grant: Seattle Genetics; Financial Interests, Personal, Other, Consultancy, honoraria: Seattle Genetics; Financial Interests, Personal, Other, Consultancy, honoraria: Takeda; Financial Interests, Personal, Other, Consultancy: Teva; Financial Interests, Personal, Research Grant: GlaxoSmithKline; Financial Interests, Personal, Other, Honoraria: GlaxoSmithKline; Financial Interests, Personal, Research Grant: ImmunoVaccine Technologies; Financial Interests, Personal, Other, Honoraria: ImmunoVaccine Technologies; Financial Interests, Personal, Research Grant: Janssen; Financial Interests, Personal, Other, Honoraria: Janssen; Financial Interests, Personal, Research Grant: Pharmacyclics; Financial Interests, Personal, Other, Honoraria: Pharmacyclics. P.L. Zinzani: Financial Interests, Personal, Other, Honoraria, board of directors or advisory committee membership, speakers’ bureau involvement: Gilead; Financial Interests, Personal, Other, Honoraria, board of directors or advisory committee membership, speakers’ bureau involvement: Incyte; Financial Interests, Personal, Other, Honoraria, speakers’ bureau involvement, consultancy: Janssen; Financial Interests, Personal, Other, Honoraria, board of directors or advisory committee membership, speakers’ bureau involvement: Kyowa Kirin; Financial Interests, Personal, Other, Honoraria, board of directors or advisory committee membership, speakers’ bureau involvement: Merck; Financial Interests, Personal, Other, Honoraria, board of directors or advisory committee membership, speakers’ bureau involvement, consultancy: MSD; Financial Interests, Personal, Other, Honoraria, board of directors or advisory committee membership, speakers’ bureau involvement: Roche; Financial Interests, Personal, Other, Honoraria, board of directors or advisory committee membership, speakers’ bureau involvement: Servier; Financial Interests, Personal, Other, Honoraria, board of directors or advisory committee membership, speakers’ bureau involvement: Takeda; Financial Interests, Personal, Other, Honoraria, speakers’ bureau involvement: TG Therapeutics; Financial Interests, Personal, Other, Honoraria, board of directors or advisory committee membership, speakers’ bureau involvement, consultancy: Verastem; Financial Interests, Personal, Other, Honoraria, board of directors or advisory committee membership, speakers’ bureau involvement: ADC Therapeutics; Financial Interests, Personal, Other, Board of directors or advisory committee membership, speakers’ bureau involvement: Celgene; Financial Interests, Personal, Other, Board of directors or advisory committee membership, speakers’ bureau involvement: Celltrion; Financial Interests, Personal, Other, Board of directors or advisory committee membership, speakers’ bureau involvement: Immune Design; Financial Interests, Personal, Other, Board of directors or advisory committee membership, speakers’ bureau involvement: Janssen-Cilag; Financial Interests, Personal, Other, Board of directors or advisory committee membership, speakers’ bureau involvement: Portola; Financial Interests, Personal, Other, Board of directors or advisory committee membership, speakers’ bureau involvement: Sandoz; Financial Interests, Personal, Other, Consultancy: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.